Scientech Research LLC Invests $289,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Scientech Research LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,619 shares of the company’s stock, valued at approximately $289,000.

Several other institutional investors also recently bought and sold shares of the stock. Jennison Associates LLC bought a new stake in Tarsus Pharmaceuticals in the first quarter valued at approximately $48,380,000. Assenagon Asset Management S.A. bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at $28,904,000. Healthcare of Ontario Pension Plan Trust Fund boosted its position in Tarsus Pharmaceuticals by 1,113.5% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after buying an additional 824,000 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Tarsus Pharmaceuticals in the 1st quarter worth $12,640,000. Finally, Millennium Management LLC increased its position in shares of Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after acquiring an additional 322,942 shares during the period. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TARS has been the subject of a number of analyst reports. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reiterated an “outperform” rating and issued a $63.00 price objective (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $51.60.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $32.89 on Tuesday. Tarsus Pharmaceuticals, Inc. has a 1 year low of $12.57 and a 1 year high of $42.50. The stock has a market capitalization of $1.25 billion, a P/E ratio of -6.90 and a beta of 1.06. The company’s 50-day moving average is $28.08 and its 200 day moving average is $31.02. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The firm had revenue of $40.81 million during the quarter, compared to analyst estimates of $31.30 million. During the same quarter in the prior year, the company earned ($1.17) EPS. On average, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.